Indications
Qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.
Composition
- Active substance
- ripretinib
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Qinlock
- Active substance
- ripretinib
- ATC code
- L01
- Therapeutic area
- Gastrointestinal Stromal Tumors
- Marketing authorisation holder
- Deciphera Pharmaceuticals (Netherlands) B.V.
- Status
- Authorised